4 results
The primary objective of the study is to assess the feasibility to treat type II endoleaks with Aneufix ACP-T5 successfully.The secondary objectives of the study are to assess the:- Clinical success rate defined asOccurrence of adverse events and…
The objective of this study is to determine the efficacy, safety, and tolerability of tafamidis in subjects with transthyretin cardiomyopathy.The primary objective is to assess the efficacy, safety, and tolerability of an oral dose of 20 mg or 80 mg…
The primary objective of the study is to assess the feasibility to treat type II endoleaks with Aneufix ACP-T5 successfully.The secondary objectives of the study are to assess the:- Clinical success rate defined as Occurrence of adverse events and…
To obtain additional, long term, safety data for tafamidis in subjects with transthyretin amyloid cardiomyopathy (ATTR CM). To provide investigational product, tafamidis, to ATTR CM subjects who complete 30 months of blinded treatment on protocol…